NovaBay Pharmaceuticals, Inc. Sustainability Profile
NovaBay Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has made significant strides in developing innovative anti-infective products, particularly in the fields of ophthalmology and dermatology. With a focus on its proprietary Avenova® solution, NovaBay offers unique antimicrobial treatments that stand out for their effectiveness and safety profile. The company has established a strong market position, recognised for its commitment to addressing unmet medical needs through advanced science. Over the years, NovaBay has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its reputation as a leader in the development of novel therapies.
DitchCarbon Score
How does NovaBay Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
NovaBay Pharmaceuticals, Inc.'s score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
NovaBay Pharmaceuticals, Inc.'s reported carbon emissions
NovaBay Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that NovaBay Pharmaceuticals may not have established formal initiatives to address carbon emissions or climate change at this time. As the pharmaceutical industry increasingly prioritises sustainability, it remains essential for companies like NovaBay to consider developing and communicating their climate strategies to align with industry standards and stakeholder expectations.
How Carbon Intensive is NovaBay Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is NovaBay Pharmaceuticals, Inc.'s Location?
NovaBay Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
NovaBay Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
